bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (104)	10/18/2014 11:58:24 PM
From: scaram(o)uche	of 163

From the "if only, if only" file..... Mario Sznol..... There will be ways to do relatively rapid isolation of cells from tumors that are tumor-antigen specific, and relatively simple ways to do rapid expansion and reinfusion. So far, the data suggests if you progress on checkpoint inhibitors, you can still respond to the cell therapies, though they may not become front-line treatments. They could become commercially available as a process where you take a piece of tumor, put it in a bag, ship it overnight, and three weeks later get back a bag of cells to infuse — then someday become a blood-bank procedure. lifescienceleader.com This sort of anecdote drives at least one person at S.I. nuts, but I hope that it's fun for some... Jim Allison and I used to talk CTLA-4 at Lair of the Bear, a family retreat (summer camp, go Camp Gold!) of U.C. Berkeley alumni assn. It was there that he first told me about the Medarex collaboration. And Walt Urba and I were grad students together in the lab of Bill Hildemann at UCLA. Walt was a total riot. Personalities behind the expertise.... both extremely nice guys. Pointer from @ColfaxCapital.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next